Communiqués Elicera Therapeutics AB

Actions

ELIC

SE0015382080

Produits pharmaceutiques

Temps Différé Nasdaq Stockholm 11:02:31 08/10/2026			Varia. 5j.	Varia. 1 janv.
2,730 ^SEK	-3,70%		-1,44%	-47,70%

17/09	Elicera Therapeutics lance la phase 2a de son essai clinique sur le lymphome à cellules B	MT
17/09	Elicera Therapeutics reçoit l'approbation de l'Agence des produits médicamenteux pour passer en phase IIa de l'étude Carma sur le lymphome à cellules B	CI

Communiqués

02/10	Elicera Therapeutics to participate in upcoming investor and partnering events	AQ
17/09	Elicera Therapeutics Receives Medical Products Agency Approval to Advance CARMA Study into Phase IIa in B-cell Lymphoma	AQ
09/09	Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma	AQ
01/09	Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors	AQ
28/08	Elicera Therapeutics: Financed for next clinical steps – Q2 review	AQ
28/08	Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate	AQ
28/08	Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2026	AQ
18/08	Elicera Therapeutics: New CEO announced	AQ
18/08	Elicera Therapeutics appoints Johan Liwing as new CEO	AQ
12/08	Elicera Therapeutics: CARMA-trial delivers another encouraging update	AQ
11/08	Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date	AQ
24/07	Elicera Therapeutics consolidates its management in Uppsala - CEO transition begins and recruitment of new CEO has started	AQ
03/07	Elicera Therapeutics: Cash runway extended	AQ
02/07	BioStock publish BioVal™ analysis of Elicera Therapeutics' ELC-301 programme	AQ
02/07	BioStock launches the rNPV platform BioVal™ and publishes its first analysis	AQ
18/06	Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma	AQ
08/06	Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board	AQ
03/06	Elicera publishes annual report for 2025	AQ
01/06	Elicera announces outcome of the rights issue	AQ
25/05	Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved	AQ
19/05	Elicera Therapeutics - Extended company presentation and Q&A	AQ
13/05	Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO	AQ
11/05	Elicera publishes information document regarding the rights issue	AQ
21/04	Elicera Therapeutics: Withdrawing fair value following rights issue announcement	AQ
21/04	Elicera Therapeutics carries out a rights issue of approximately SEK 73 million	AQ